# PDUFA dates May 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-05

> 539 FDA catalysts are dated in May 2025, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in May 2025?

PDUFA dates in May 2025: FAKZYNJA (defactinib, VSTM) on May 8, 2025; VYGLXIA (troriluzole, BHVN) on May 14, 2025; ZORYVE (roflumilast, ARQT) on May 22, 2025; YUTREPIA (treprostinil, LQDA) on May 24, 2025; DPI (dpi, LQDA) on May 24, 2025; MK-6482 (MRK) on May 26, 2025; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-05)

Source: SEC Form 10-Q, accession 0001104659-25-106279, https://www.sec.gov/Archives/edgar/data/1526119/000110465925106279/vstm-20250930x10q.htm (retrieved 2026-11-12). Last confirmed 2025-11-04. Cite: https://sec-api.dev/fda-calendar/2025-05#answer

## PDUFA dates in May 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| May 8, 2025 | Verastem, Inc. | VSTM | FAKZYNJA (defactinib) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465925106279/vstm-20250930x10q.htm) |
| May 14, 2025 | Biohaven Ltd. | BHVN | VYGLXIA (troriluzole) | spinocerebellar ataxia | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm) |
| May 22, 2025 | Arcutis Biotherapeutics, Inc. | ARQT | ZORYVE (roflumilast) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm) |
| May 24, 2025 | Liquidia Corp | LQDA | YUTREPIA (treprostinil) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925046935/tm2514743d1_ex99-1.htm) |
| May 24, 2025 | Liquidia Corp | LQDA | DPI (dpi) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm) |
| May 26, 2025 | Merck & Co., Inc. | MRK | MK-6482 |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm) |
| May 28, 2025 | Eton Pharmaceuticals, Inc. | ETON | ET-400 |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/eton20250205_8k.htm) |
| May 31, 2025 | Moderna, Inc. | MRNA |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm) |

## All catalysts in May 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 1, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| May 1, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/exhibit991-1q25earningsrel.htm)) |
| May 1, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong first quarter 2025 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/exhibit991-q12025pressrele.htm)) |
| May 1, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports first-quarter 2025 financial results and highlights pipeline momentum" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm)) |
| May 1, 2025 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465925043014/tm2513585d1_ex99-1.htm)) |
| May 1, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/alks-ex99_1.htm)) |
| May 1, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm)) |
| May 1, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/a991earningsreleasedatedma.htm)) |
| May 1, 2025 | [KOMET-015 trial start](https://sec-api.dev/pdufa/komet-015) | KURA | advanced gastrointestinal stromal tumors | completed | "First patients dosed in KOMET-015 trial in GIST - Earlier this week, Kura announced the first patients have been dosed in its KOMET-015 Phase 1 clinical trial of ziftomenib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-ex99_1.htm)) |
| May 1, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm)) |
| May 1, 2025 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/adpt-ex99_1.htm)) |
| May 1, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/fulc-ex99_1.htm)) |
| May 1, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/ardx-20250331xexhibit991.htm)) |
| May 1, 2025 | [Ivonescimab earnings report](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed | "1 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic NSCLC Ivonescimab Collaborations Progressing in Multiple Solid Tumor Settings: MD Anderson Collaboration Begins Enrolling Two Clinical Trials" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/a2025_prx0501xq12025earn.htm)) |
| May 1, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/tm2513730d1_ex99-1.htm)) |
| May 1, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-ex99_1.htm)) |
| May 1, 2025 | [ABVC BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/abvc/catalysts) | ABVC |  | completed | "Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, oncology, and ophthalmology indications, today announced its financial results for the first quarter ended March 31, 2025, and shared updates on its strategic plan to explore the development of an AI-enabled agricultural facility in Taiwan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025038060/ea024006301ex99-1_abvcbio.htm)) |
| May 1, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/amgn-20250331earningsrelea.htm)) |
| May 1, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/earningsrelease-1may25ex991.htm)) |
| May 1, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/d847727dex991.htm)) |
| May 1, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/nxtc-20250501xex99d1.htm)) |
| May 1, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/exhibit991tarsus512025pres.htm)) |
| May 1, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/sttk_q12025earningspr.htm)) |
| May 1, 2025 | [Lumvoa™ (veligrotug) primary completion](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547)) |
| May 2, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| May 2, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/amrx-q12025ex991.htm)) |
| May 2, 2025 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Fiscal Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072025000024/ibio-20250502xex99d1.htm)) |
| May 2, 2025 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today reported financial results and business highlights for the second quarter of fiscal 2025 ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000110465925044352/tm2513694d1_ex99-1.htm)) |
| May 2, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Chronic Migraine | completed | "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05216263)) |
| May 3, 2025 | [Optic white 5%hp activshine toothpaste primary completion](https://sec-api.dev/pdufa/optic-white-5-hp-activshine-toothpaste) | CL | Whitening | completed | "NCT06957249 (Clinical Study to Evaluate the Tooth Whitening Efficacy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-03 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06957249)) |
| May 5, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/q1-2025xearningsrelease.htm)) |
| May 5, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_ex99-1.htm)) |
| May 5, 2025 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/bmea-ex99_1.htm)) |
| May 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/ef20048524_ex99-1.htm)) |
| May 5, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/exh_991.htm)) |
| May 5, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/imrx-20250505xexx991.htm)) |
| May 5, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/exhibit991pressrelease0505.htm)) |
| May 5, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm)) |
| May 5, 2025 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/xncr-20250507xexx991.htm)) |
| May 5, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/exhibit991-q0125.htm)) |
| May 5, 2025 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000095017025063540/oric-ex99_1.htm)) |
| May 5, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm)) |
| May 5, 2025 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Anaptys Announces First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/q12025earningsrelease.htm)) |
| May 5, 2025 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/rlay-ex99_1.htm)) |
| May 5, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/ex_811168.htm)) |
| May 5, 2025 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325002743/exh_991.htm)) |
| May 5, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/ex-991_q12025.htm)) |
| May 5, 2025 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Healthy Volunteers | completed | "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060067)) |
| May 6, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-ex99_1.htm)) |
| May 6, 2025 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/a2025q18kexhibit991.htm)) |
| May 6, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS First QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925014917/ex_763001.htm)) |
| May 6, 2025 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/exh_991.htm)) |
| May 6, 2025 | [YARTEMLEA® (narsoplimab) NDA/BLA acceptance](https://sec-api.dev/pdufa/narsoplimab) | OMER | hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed | "On May 6, 2025, Omeros Corporation issued a press release announcing that the U.S. Food and Drug Administration accepted for review the resubmission of the Biologics License Application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774925014815/omer20250506_8k.htm)) |
| May 6, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm)) |
| May 6, 2025 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000095017025064423/acet-ex99_1.htm)) |
| May 6, 2025 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports First-Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000147824225000082/iqv-q1x2025earningspressre.htm)) |
| May 6, 2025 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/a1q25earningspressrelease.htm)) |
| May 6, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/ex991snti2025q125earningsr.htm)) |
| May 6, 2025 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/lab-ex99_1.htm)) |
| May 6, 2025 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/bioa-ex99_1.htm)) |
| May 6, 2025 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000084914625000041/earningsrelease_q3fy25.htm)) |
| May 6, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea024082701ex99-1_cormedix.htm)) |
| May 6, 2025 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/okur-ex99_1.htm)) |
| May 6, 2025 | [Elraglusib topline data readout](https://sec-api.dev/pdufa/elraglusib) | ACTU |  | completed, met | "As previously announced on May 6, 2025, the Company's topline Phase 2 data of elraglusib in combination with GnP met the primary endpoints of the trial and achieved statistical significance in topline results from its ongoing Phase 2 (Actuate-1801 Part 3B) trial in first-line treatment of mPDAC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1652935/000168316825004117/actuate_8k.htm)) |
| May 6, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, May 6, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/a1q25exhibit991pr.htm)) |
| May 6, 2025 | [TAXOL® (paclitaxel) topline data readout](https://sec-api.dev/pdufa/paclitaxel) | ACTU | high-impact, difficult-to-treat cancers | completed, met | "CHICAGO, IL and FORT WORTH, TX, May 6, 2025 - Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results from its ongoing Phase 2 (Actuate-1801 Part" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1652935/000168316825003163/actuate_ex9901.htm)) |
| May 6, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/d937417dex991.htm)) |
| May 6, 2025 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/d923057dex991.htm)) |
| May 6, 2025 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/crbp-ex99_1.htm)) |
| May 6, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000104/ex991pressreleaseq12025.htm)) |
| May 6, 2025 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "(NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2025 and provided an update on recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/tm2514104d1_ex99-1.htm)) |
| May 6, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., May 6, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-ex99_1.htm)) |
| May 6, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm)) |
| May 6, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/tm2514128d1_ex99-1.htm)) |
| May 6, 2025 | [Beam Therapeutics Inc. earnings report](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | completed | "Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/beam-ex99_1.htm)) |
| May 6, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q1 2025 FINANCIAL RESULTS, HIGHLIGHTS ADVANCEMENT OF ITS PIPELINE AND UPCOMING CATALYSTS, AND REAFFIRMS 2025 REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506xex99d1.htm)) |
| May 6, 2025 | [BioAtla, Inc. earnings report](https://sec-api.dev/companies/bcab/catalysts) | BCAB |  | completed | "BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/bcab-ex99_1.htm)) |
| May 6, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "Cogent Biosciences Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-ex99_1.htm)) |
| May 6, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| May 6, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm)) |
| May 6, 2025 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000095017025064429/sprb-ex99_1.htm)) |
| May 6, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/ex991q120258-k.htm)) |
| May 6, 2025 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/tcrx-ex99_1.htm)) |
| May 6, 2025 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528025000201/exhibit99q12025.htm)) |
| May 6, 2025 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000095017025063954/upb-ex99_1.htm)) |
| May 6, 2025 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "ZUG, Switzerland and BOSTON, Mass. - May 6, 2025-- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/crsp-ex99_1.htm)) |
| May 6, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm)) |
| May 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/tm2514117d1_ex99-1.htm)) |
| May 6, 2025 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/ex991earningspr.htm)) |
| May 6, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-ex99_1.htm)) |
| May 6, 2025 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Recent First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/exhibit991q12025.htm)) |
| May 6, 2025 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/prld-ex99_1.htm)) |
| May 2025 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | delayed | "NCT03944772 (Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03944772)) |
| May 6, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate to Severe Atopic Dermatitis | completed | "NCT06136741 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136741)) |
| May 6, 2025 | [REC-3964 primary completion](https://sec-api.dev/pdufa/rec-3964) | RXRX | Recurrent Clostridioides Difficile Infection | withdrawn | "NCT06536465 (The Clostridioides Difficile Trial of REC-3964): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2025-11-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06536465)) |
| May 7, 2025 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "WILMINGTON, MA, May 7, 2025 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068225000019/crl1q25earningsrelease.htm)) |
| May 7, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/amph-20250507xex99d1.htm)) |
| May 7, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/ebs2025-03x31ex99earningsr.htm)) |
| May 7, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Calif. - May 7, 2025 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/tm2514212d1_ex99-1.htm)) |
| May 7, 2025 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm)) |
| May 7, 2025 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828025023175/a20250507-q1ex991earningsr.htm)) |
| May 7, 2025 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910425000040/elanco-20250331exhibit991.htm)) |
| May 7, 2025 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536425000054/cy25q1ex991pressrelease.htm)) |
| May 7, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Strong First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/sdgr-20250331xexx991.htm)) |
| May 7, 2025 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000095017025064980/amrn-ex99_1.htm)) |
| May 7, 2025 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000095017025065703/tnya-ex99_1.htm)) |
| May 7, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm)) |
| May 7, 2025 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/inab-ex99_1.htm)) |
| May 7, 2025 | [Theriva (theriva) topline data readout](https://sec-api.dev/pdufa/theriva) | TOVX | cancer and related diseases in areas of high unmet need, today | completed, positive | "MD, May 07, 2025 - Theriva™ Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/tm2514050d1_ex99-1.htm)) |
| May 7, 2025 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/rvmd-ex99_1.htm)) |
| May 7, 2025 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/May 7, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000155837025006594/tech-20250507xex99d1.htm)) |
| May 7, 2025 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/mxct-20250507xex99d1.htm)) |
| May 7, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/exh_991.htm)) |
| May 7, 2025 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/cccc-20250507xexx991.htm)) |
| May 7, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507xexx991.htm)) |
| May 7, 2025 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "2025, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/tm2514334d1_ex99-1.htm)) |
| May 7, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| May 7, 2025 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000155837025006760/pahc-20250507xex99d1.htm)) |
| May 7, 2025 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm)) |
| May 7, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177dex991.htm)) |
| May 7, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Pharmaceuticals Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/tm2514185d1_ex99-1.htm)) |
| May 7, 2025 | [Zabilugene almadenorepvec topline data readout](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | completed, positive | "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating our lead product candidate VCN-01 (zabilugene almadenorepvec) plus SoC chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with mPDAC for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm)) |
| May 7, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-ex99_1.htm)) |
| May 7, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-ex99_1.htm)) |
| May 7, 2025 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/tm2514197d1_ex99-1.htm)) |
| May 7, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm)) |
| May 7, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeiGene Announces First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/exhibit991-q12025earningsr.htm)) |
| May 7, 2025 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/krro-ex99_1.htm)) |
| May 7, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm)) |
| May 7, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm)) |
| May 7, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm)) |
| May 7, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000074/q12025eolsex991.htm)) |
| May 7, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports first quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/ef20048471_ex99-1.htm)) |
| May 7, 2025 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Hypereosinophilic Syndrome | completed | "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04191304)) |
| May 7, 2025 | [Darvadstrocel primary completion](https://sec-api.dev/pdufa/darvadstrocel) | TAK | Crohn's Disease; Complex Perianal Fistula | withdrawn | "NCT04701411 (A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04701411)) |
| May 7, 2025 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjogren Syndrome | completed | "NCT05350072 (Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05350072)) |
| May 7, 2025 | [AD109 primary completion](https://sec-api.dev/pdufa/ad109) | APMD | OSA | completed | "NCT05811247 (Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Apnimed; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811247)) |
| May 7, 2025 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | Atypical Hemolytic Uremic | completed | "NCT05876351 (Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2025-12-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05876351)) |
| May 8, 2025 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/a03312025ex991.htm)) |
| May 8, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Boulder, Colo., (May 8, 2025) - Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_ex99-1.htm)) |
| May 8, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports First Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/a1q25earningspressreleased.htm)) |
| May 8, 2025 | [FAKZYNJA (defactinib) PDUFA date](https://sec-api.dev/pdufa/defactinib) | VSTM |  | scheduled | "On May 8, 2025, the FDA approved AVMAPKI FAKZYNJA CO-PACK in advance of its Prescription Drug User Fee Act or PDUFA action date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465925106279/vstm-20250930x10q.htm)) |
| May 8, 2025 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/pepg-ex99_1.htm)) |
| May 8, 2025 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/ea024114801ex99-1_longeveron.htm)) |
| May 8, 2025 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/coll-20250508xex99d1.htm)) |
| May 8, 2025 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "BOSTON, Mass. and SAN DIEGO, Calif. - May 8, 2025 - Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the first quarter ending March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/rapp-ex99_1.htm)) |
| May 8, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/dyn-ex99_1.htm)) |
| May 8, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025023410/zlab-202558x8kex991.htm)) |
| May 8, 2025 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates May 8, 2025 at 7:00 AM EDT Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/autlex-991pr080525.htm)) |
| May 8, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508xex99d1.htm)) |
| May 8, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/vyne-20250508q12025exx991.htm)) |
| May 8, 2025 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/q120258-kex991xpressrelease.htm)) |
| May 8, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/exh_991.htm)) |
| May 8, 2025 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000055/ser-20250508xex991_earning.htm)) |
| May 8, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/ex991earningsrelease1q25fi.htm)) |
| May 8, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/ex991earningsreleaseq12025.htm)) |
| May 8, 2025 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-ex99_1.htm)) |
| May 8, 2025 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/alxo-ex99_1.htm)) |
| May 8, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/d937042dex991.htm)) |
| May 8, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea024092901ex99-1_protara.htm)) |
| May 8, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_ex99-1.htm)) |
| May 8, 2025 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325002952/exh_991.htm)) |
| May 8, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/glue-ex99_1.htm)) |
| May 8, 2025 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces First-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/ex99-1.htm)) |
| May 8, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/crbu-20250508xexx991.htm)) |
| May 8, 2025 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm)) |
| May 8, 2025 | [Nimacimab earnings report](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | completed | "Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250331xearningspr.htm)) |
| May 8, 2025 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/exhibit991_earningsrelease.htm)) |
| May 8, 2025 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/a2025q1ex991.htm)) |
| May 8, 2025 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000095017025066947/crdf-ex99_1.htm)) |
| May 8, 2025 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/tecx-ex99_1.htm)) |
| May 8, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025067061/stro-ex99_1.htm)) |
| May 8, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-3312025x991.htm)) |
| May 8, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/d932196dex991.htm)) |
| May 8, 2025 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "ATLANTA, Ga., May 8, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/dwtx-20250508xex99d1.htm)) |
| May 8, 2025 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/ex99-1.htm)) |
| May 8, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/q12025pressrelease.htm)) |
| May 8, 2025 | [AbCellera Biologics Inc. earnings report](https://sec-api.dev/companies/abcl/catalysts) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/q12025earningspressrelease.htm)) |
| May 8, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm)) |
| May 8, 2025 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm)) |
| May 8, 2025 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/entradatherapeuticsreports.htm)) |
| May 8, 2025 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525115489/d892783dex991.htm)) |
| May 8, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/rlyb-2025058xex991pressrel.htm)) |
| May 8, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325002954/exh_991.htm)) |
| May 8, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/q12025pr1.htm)) |
| May 8, 2025 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 8, 2025-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594725000014/exhibit991fy25-q4earningsr.htm)) |
| May 8, 2025 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/asmb-ex99_1.htm)) |
| May 8, 2025 | [SPY003 trial start](https://sec-api.dev/pdufa/spy003) | SYRE |  | completed | "Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and safety data readout on track for the second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| May 8, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/artv-ex99_1.htm)) |
| May 8, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, including obesity, today reported financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm)) |
| May 8, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/nams-ex99_1.htm)) |
| May 8, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/ea0241353ex99-1_nektar.htm)) |
| May 8, 2025 | [Cadrenal Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cvkd/catalysts) | CVKD |  | completed | "8, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/ea024139701ex99-1_cadrenal.htm)) |
| May 8, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_ex99-1.htm)) |
| May 8, 2025 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025066366/qttb-ex99_1.htm)) |
| May 8, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/amlx-ex99_1.htm)) |
| May 8, 2025 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905325000022/exhibit991q12025earningsre.htm)) |
| May 8, 2025 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/a1q2025exhibit991.htm)) |
| May 8, 2025 | [Avmapki Fakzynja Co-Pack (Copackaged) (avutometinib potassium; defactinib hydrochloride) FDA approval](https://sec-api.dev/pdufa/avutometinib-defactinib) | VSTM |  | completed, approved | "NDA219616 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250508, review_priority PRIORITY; sponsor_name VERASTEM INC; product AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219616%22)) |
| May 8, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| May 8, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/q12025earningsrelease_ex991.htm)) |
| May 8, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/ex_785138.htm)) |
| May 8, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/exh991q12025earningsrelease.htm)) |
| May 8, 2025 | [AVMAPKI (avutometinib) FDA approval](https://sec-api.dev/pdufa/avutometinib) | VSTM | RAS/MAPK pathway-driven cancers, today | completed, approved | "On May 8, 2025, Verastem, Inc. issued a press release announcing that the United States Food and Drug Administration ("FDA") has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with recurrent Kirsten rat sarcoma viral oncogene homolog mutated ("KRAS mt") low-grade serous ovarian cancer ("LGSOC") who received prior systemic therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465925046175/tm2514525d1_8k.htm)) |
| May 8, 2025 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/tm2514493d1_ex99-1.htm)) |
| May 8, 2025 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/trvi-ex99_1.htm)) |
| May 8, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000016/exhibit991-1q25earningsrel.htm)) |
| May 8, 2025 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/sana-ex99_1.htm)) |
| May 8, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm)) |
| May 8, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-1.htm)) |
| May 8, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/cgem-ex99_1.htm)) |
| May 8, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/tyra-ex99_1.htm)) |
| May 8, 2025 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "WALTHAM, Mass., May 8, 2025 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/xlo-20250508xex99d1.htm)) |
| May 8, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/aadi-20250508xex991.htm)) |
| May 8, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "May 8, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-ex99_1.htm)) |
| May 8, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/janx-ex99_1.htm)) |
| May 8, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/orgo-ex99_1.htm)) |
| May 8, 2025 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/ex991q12025_earningsxrelea.htm)) |
| May 8, 2025 | [Inmune Bio, Inc. earnings report](https://sec-api.dev/companies/inmb/catalysts) | INMB |  | completed | "Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/ea024145301ex99-1_inmune.htm)) |
| May 8, 2025 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/tm2514121d1_ex99-1.htm)) |
| May 8, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125017954/ef20048574_ex99-1.htm)) |
| May 8, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS FIRST QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/d938501dex991.htm)) |
| May 8, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm)) |
| May 8, 2025 | [Ustekinumab dose based on bsa and body weight primary completion](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028)) |
| May 8, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Metastatic Esophageal Squamous Cell Carcinoma | withdrawn | "NCT04949256 (Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04949256)) |
| May 8, 2025 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | completed | "NCT05452070 (A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Allergan." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05452070)) |
| May 8, 2025 | [Daxdilimab primary completion](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Discoid Lupus Erythematosus | withdrawn | "NCT05591222 (Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05591222)) |
| May 8, 2025 | [Awiqli Flextouch (insulin icodec) primary completion](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes, Type 2 | completed | "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340854)) |
| May 8, 2025 | [Obeldesivir primary completion](https://sec-api.dev/pdufa/obeldesivir) | GILD | RSV Infection | withdrawn | "NCT06585150 (Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585150)) |
| May 8, 2025 | [Oral evo756 300 mg qd primary completion](https://sec-api.dev/pdufa/oral-evo756) | EVMN | Chronic Inducible Urticaria | completed | "NCT06603220 (A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Evommune, Inc.; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603220)) |
| May 9, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/anip-20250509xexx991.htm)) |
| May 9, 2025 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/ex991-pressreleasemarch312.htm)) |
| May 9, 2025 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/tm2514854d1_ex99-1.htm)) |
| May 9, 2025 | [Stenoparib trial start](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "Combination Trial Launched: Allarity announced a new Phase 2 trial evaluating stenoparib in combination with temozolomide for recurrent small cell lung cancer (SCLC), fully funded by the U.S. Veterans Administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/ex_815151.htm)) |
| May 9, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/d27625dex991.htm)) |
| May 9, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/pmvp-ex99_1.htm)) |
| May 9, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-ex99_1.htm)) |
| May 9, 2025 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465925046502/tm2514473d1_ex99-1.htm)) |
| May 9, 2025 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/srzn-ex99_1.htm)) |
| May 9, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509xex99d1.htm)) |
| May 9, 2025 | [ZEVASKYN (zevaskyn) FDA approval](https://sec-api.dev/pdufa/zevaskyn) | ABEO |  | completed, approved | "May 9, 2025, the Company entered into a definitive asset purchase agreement that transferred the rights to a PRV awarded to the Company following the FDA approval of ZEVASKYN®." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/form10-k.htm)) |
| May 9, 2025 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000044/ngne_1q2025release.htm)) |
| May 9, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 9, 2025 GLOBE NEWSWIRE) - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn20250509ex991.htm)) |
| May 9, 2025 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/bold-ex99_1.htm)) |
| May 9, 2025 | [Celularity Inc earnings report](https://sec-api.dev/companies/celu/catalysts) | CELU |  | completed | "Announces Full Year 2024 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/ex99-1.htm)) |
| May 9, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-ex99_1.htm)) |
| May 9, 2025 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Bio Announces First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/exhibit_99-1.htm)) |
| May 9, 2025 | [Stenoparib earnings report](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on recent operational highlights for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/ex_815151.htm)) |
| May 9, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/plx-20250509xex99d1.htm)) |
| May 9, 2025 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | Cervical Cancer; Colorectal Cancer; Esophageal Cancer | withdrawn | "NCT05563272 (89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05563272)) |
| May 9, 2025 | [ASTRAZENECA PLC primary completion](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123)) |
| May 10, 2025 | [CAEL-101 primary completion](https://sec-api.dev/pdufa/cael-101) | AZN | AL Amyloidosis | completed | "NCT04504825 (A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04504825)) |
| May 10, 2025 | [REGN1908 primary completion](https://sec-api.dev/pdufa/regn1908) | REGN | Allergic Conjunctivitis | completed | "NCT06602726 (A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602726)) |
| May 12, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-ex99_1.htm)) |
| May 12, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/bolt-ex99_1.htm)) |
| May 12, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512xex99d1.htm)) |
| May 12, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512xex99d1.htm)) |
| May 12, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm)) |
| May 12, 2025 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/bdtx-exhibit991_q12025.htm)) |
| May 12, 2025 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/d923851dex991.htm)) |
| May 12, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/ex_816257.htm)) |
| May 12, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm)) |
| May 12, 2025 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Reports First Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/ex99-01.htm)) |
| May 12, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Q1 2025 Financial Results and Key Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/agen-ex99_1.htm)) |
| May 12, 2025 | [CX-2051 interim data readout](https://sec-api.dev/pdufa/cx-2051) | CTMX |  | completed, positive | "May 12, 2025, we announced positive interim data from our ongoing Phase 1 dose escalation study of EpCAM Antibody Drug Conjugate (CX-2051) in patients with advanced colorectal cancer." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1501989/000119312525117880/d47164d424b5.htm)) |
| May 12, 2025 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/ex-9911q2025earningsrelease.htm)) |
| May 12, 2025 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/mbx-ex99_1.htm)) |
| May 12, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-ex99_1.htm)) |
| May 12, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif. — May 12, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/ibrx-2025512x8kexhibit991.htm)) |
| May 12, 2025 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000095017025069156/annx-ex99_1.htm)) |
| May 12, 2025 | [Briquilimab earnings report](https://sec-api.dev/pdufa/briquilimab) | JSPR |  | completed | "- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2025 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/ea024173201ex99-1_jasper.htm)) |
| May 12, 2025 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323925000062/exhibit991-q12025.htm)) |
| May 12, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/e664482_ex99-1.htm)) |
| May 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Conn., May 12, 2025 — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia is fully enrolled." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_ex99-1.htm)) |
| May 12, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/ex99-1.htm)) |
| May 12, 2025 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000095017025069183/xene-ex99_1.htm)) |
| May 12, 2025 | [XPOVIO® (selinexor) earnings report](https://sec-api.dev/pdufa/selinexor) | KPTI |  | completed | "Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/kpti-ex99_1.htm)) |
| May 12, 2025 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces First Quarter 2025 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/editasmedicinepressrelease.htm)) |
| May 12, 2025 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - May 12, 2025 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/catx-ex99_1.htm)) |
| May 12, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/ex_799147.htm)) |
| May 12, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-ex99_1.htm)) |
| May 12, 2025 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Michigan, May 12, 2025 - Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000110465925046957/tm2514651d1_ex99-1.htm)) |
| May 12, 2025 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/exh_991.htm)) |
| May 12, 2025 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000203604225000014/sion1q25earningsrelease.htm)) |
| May 12, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2025 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_ex99-1.htm)) |
| May 12, 2025 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/d23036dex991.htm)) |
| May 12, 2025 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q1 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/dnth-ex99_1.htm)) |
| May 12, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/rgnx-ex99_1.htm)) |
| May 12, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/q12025-ex991earningsrelease.htm)) |
| May 12, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| May 12, 2025 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/nmra-ex99_1.htm)) |
| May 12, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/exhibit991_q12025earningsr.htm)) |
| May 12, 2025 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-202505128kex991.htm)) |
| May 12, 2025 | [REDEMPLO (plozasiran) NDA/BLA acceptance](https://sec-api.dev/pdufa/plozasiran) | ARWR | familial chylomicronemia syndrome | completed | "•Announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-202505128kex991.htm)) |
| May 12, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm)) |
| May 12, 2025 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| May 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/cue-ex99_1.htm)) |
| May 12, 2025 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/prok-ex99_1.htm)) |
| May 12, 2025 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/moonlake-pressreleasexq120.htm)) |
| May 12, 2025 | [Dn-tnf primary completion](https://sec-api.dev/pdufa/dn-tnf) | INMB | Alzheimer Disease; Dementia; Brain Diseases | completed | "NCT05318976 (A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-12 (ACTUAL); Lead Sponsor Inmune Bio, Inc.; Results First Posted 2026-06-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05318976)) |
| May 13, 2025 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000095017025069811/mreo-ex99_1.htm)) |
| May 13, 2025 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Reports Business Updates and First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/mgx-ex99_1.htm)) |
| May 13, 2025 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports First Quarter 2025 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/eras-ex99_1.htm)) |
| May 13, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "Conn. - May 13, 2025 — Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/ex99-1.htm)) |
| May 13, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, May 13, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/ex_815119.htm)) |
| May 13, 2025 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/tpst-ex99_1.htm)) |
| May 13, 2025 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports First Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/ex_762500.htm)) |
| May 13, 2025 | [Allogene Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allo/catalysts) | ALLO |  | completed | "Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/allo-20250331xexx991q125.htm)) |
| May 13, 2025 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "Adaptimmune Reports Q1 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837025007493/adap-20250513xex99d1.htm)) |
| May 13, 2025 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/lyel-20250513x8kexx991.htm)) |
| May 13, 2025 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000095017025069818/atos-ex99_1.htm)) |
| May 13, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid2025q1exhibit991.htm)) |
| May 13, 2025 | [ELI-002 earnings report](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival ("DFS") in randomized Phase 2 AMPLIFY- 7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration ("FDA") on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate and clinical updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm)) |
| May 13, 2025 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/coya-ex99_1.htm)) |
| May 13, 2025 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/q1-25er.htm)) |
| May 13, 2025 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000037/a20250513form8-kxexhibit991.htm)) |
| May 13, 2025 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/kytx-ex99_1.htm)) |
| May 13, 2025 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "Company) today reported its consolidated first-quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312525120763/d63848dex991.htm)) |
| May 13, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/huma-20250513xexx991.htm)) |
| May 13, 2025 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/ex_816889.htm)) |
| May 13, 2025 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000155837025007487/pasg-20250513xex99d1.htm)) |
| May 13, 2025 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical- stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/tm2515088d1_ex99-1.htm)) |
| May 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/tm2514904d1_ex99-1.htm)) |
| May 13, 2025 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/exhibit991-q125.htm)) |
| May 13, 2025 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/pressreleaseq12025.htm)) |
| May 13, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "(Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_ex99-1.htm)) |
| May 13, 2025 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 13, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS"" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/ea024198601ex99-1_therap.htm)) |
| May 13, 2025 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/mgtx-20250513xex99d1.htm)) |
| May 13, 2025 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces First Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/alt-20250513xex99d1.htm)) |
| May 13, 2025 | [CABOMETYX® (cabozantinib) FDA approval](https://sec-api.dev/pdufa/cabozantinib) | EXEL |  | completed, approved | "In March, Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm)) |
| May 13, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm)) |
| May 13, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/ex_811087.htm)) |
| May 13, 2025 | [ET-600 NDA/BLA submission](https://sec-api.dev/pdufa/et-600) | ETON |  | completed | "Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/ex_811087.htm)) |
| May 13, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635dex991.htm)) |
| May 13, 2025 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/ex99-1.htm)) |
| May 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/ex_817334.htm)) |
| May 13, 2025 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/aura-ex99_1.htm)) |
| May 13, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/ex99-1.htm)) |
| May 13, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-ex99_1.htm)) |
| May 13, 2025 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, May 13, 2025 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282225000027/pressreleaseearningsq105-1.htm)) |
| May 13, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-202505138xkexhibit991.htm)) |
| May 13, 2025 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000095017025069783/stok-ex99_1.htm)) |
| May 13, 2025 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/tm2514876d1_ex99-1.htm)) |
| May 13, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm)) |
| May 13, 2025 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "GRAND CAYMAN, Cayman Islands, May 13, 2025 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on recent business developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm)) |
| May 13, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| May 13, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/d88474dex991.htm)) |
| May 13, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/rani-ex99_1.htm)) |
| May 13, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "ROCKVILLE, MD., May 13, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/exhibit99-1earningspressre.htm)) |
| May 13, 2025 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/ints20250513ex99120250331p.htm)) |
| May 13, 2025 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/lctx-ex99_1.htm)) |
| May 13, 2025 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "MA - May 13, 2025 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465925047564/tm2514827d1_ex99-1.htm)) |
| May 13, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/fate-ex99_1.htm)) |
| May 13, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, May 13, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/exhibit991-2025q110xqpr.htm)) |
| May 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/cadl-ex99_1.htm)) |
| May 13, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm)) |
| May 13, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/abos-20250513xexx991.htm)) |
| May 13, 2025 | [Anebulo Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/aneb/catalysts) | ANEB |  | completed | "Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/ex99-1.htm)) |
| May 13, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, May 13, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/olma-ex99_1.htm)) |
| May 13, 2025 | [Dbv712 250 mcg primary completion](https://sec-api.dev/pdufa/dbv712) | DBVT | Peanut Allergy | completed | "NCT03859700 (Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor DBV Technologies; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03859700)) |
| May 13, 2025 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjogren Syndrome | completed | "NCT05349214 (Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05349214)) |
| May 13, 2025 | [Cspr toothpaste primary completion](https://sec-api.dev/pdufa/cspr-toothpaste) | CL | Sensitivity, Tooth | completed | "NCT06960148 (Dentinal Hypersensitivity Reduction Efficacy Study): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960148)) |
| May 14, 2025 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000095017025071474/kod-ex99_1.htm)) |
| May 14, 2025 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/exh_991.htm)) |
| May 14, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/tm2514979d1_ex99-1.htm)) |
| May 14, 2025 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000095017025071477/ck0001774857-ex99_1.htm)) |
| May 14, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| May 14, 2025 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/ex_778276.htm)) |
| May 14, 2025 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "(NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025 operating and financial results and reviewed recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm)) |
| May 14, 2025 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/apre-20250514xex99d1.htm)) |
| May 14, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/ea024197401ex99-1_citius.htm)) |
| May 14, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-ex99_1.htm)) |
| May 14, 2025 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/nktx-ex99_1.htm)) |
| May 14, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/ea024197201ex99-1_citius.htm)) |
| May 14, 2025 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/clym-ex99_1.htm)) |
| May 14, 2025 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000095017025071382/tennx-ex99_1.htm)) |
| May 14, 2025 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/ef20048917_ex99-1.htm)) |
| May 14, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-ex99_1.htm)) |
| May 14, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735dex991.htm)) |
| May 14, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925048160/tm2515019d1_ex99-1.htm)) |
| May 14, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/exhibit99103312025.htm)) |
| May 14, 2025 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/exh_991.htm)) |
| May 14, 2025 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774925016840/ex_817681.htm)) |
| May 14, 2025 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen Reports First Quarter 2025 Financial Results and Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/dp228863_ex9901.htm)) |
| May 14, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/ex_793225.htm)) |
| May 14, 2025 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225010098/ex99-1.htm)) |
| May 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "May 14, 2025  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (PAH), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/d940084dex991.htm)) |
| May 14, 2025 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/xenetic_ex9901.htm)) |
| May 14, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514xex99d1.htm)) |
| May 14, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/ganx-20250514xex99d1.htm)) |
| May 14, 2025 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE)  Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or Company), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference (ddRNAi) platform, today announced financial results for its third fiscal quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312525119402/d52557dex991.htm)) |
| May 14, 2025 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "SAN DIEGO, May 14, 2025 - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2025 and provided an update on the continued U.S. commercial launch of neffy® (epinephrine nasal spray), the first and only FDA approved and European Commission approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-ex99_1.htm)) |
| May 14, 2025 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774925016598/ex_817237.htm)) |
| May 14, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm)) |
| May 14, 2025 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/acrv-ex99_1.htm)) |
| May 14, 2025 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "Dyadic Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/ex_762968.htm)) |
| May 14, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514xex99d1.htm)) |
| May 14, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/aeon-20250514xex99.htm)) |
| May 14, 2025 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250514, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| May 14, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/adct-20250331pressrelease.htm)) |
| May 14, 2025 | [Rapamycin interim data readout](https://sec-api.dev/pdufa/rapamycin) | QNRX |  | completed, positive | "On May 14, 2025, the Company announced positive initial data from its investigator led Peeling Skin Syndrome (PSS) clinical study which is being conducted in a single patient in New Zealand." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_ex99-1.htm)) |
| May 14, 2025 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Mass., May 14, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/ex99-1.htm)) |
| May 14, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514xex99d1.htm)) |
| May 14, 2025 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports First Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/ex_817956.htm)) |
| May 14, 2025 | [Brekiya (Autoinjector) (dihydroergotamine mesylate) FDA approval](https://sec-api.dev/pdufa/dihydroergotamine) | AMRX |  | completed, approved | "NDA215400 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250514, review_priority STANDARD; sponsor_name AMNEAL; product BREKIYA (AUTOINJECTOR) (DIHYDROERGOTAMINE MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215400%22)) |
| May 14, 2025 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/tm2514864d1_ex99-1.htm)) |
| May 14, 2025 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312525119856/d72148dex993.htm)) |
| May 14, 2025 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/elvn-ex99_1.htm)) |
| May 14, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/ck0001534133-ex99_1.htm)) |
| May 14, 2025 | [VYGLXIA (troriluzole) PDUFA date](https://sec-api.dev/pdufa/troriluzole) | BHVN | spinocerebellar ataxia | scheduled | "On May 14, 2025, Biohaven Ltd. (the "Company" or "Biohaven") issued a press release announcing that the Division of Neurology 1 (the "Division") within the U.S. Food and Drug Administration's ("FDA") Office of Neuroscience informed the Company that they are extending the Prescription Drug User Fee Act ("PDUFA") date for the troriluzole new drug application (the "NDA") for the treatment of spinocerebellar ataxia by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm)) |
| May 14, 2025 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/zntl_q12025earningspr.htm)) |
| May 14, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-ex99_1.htm)) |
| May 14, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/ex99-1.htm)) |
| May 14, 2025 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (May 14, 2025) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/ex_817674.htm)) |
| May 14, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904dex991.htm)) |
| May 14, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514xex99d1.htm)) |
| May 14, 2025 | [Pembrolizumab (keytruda®) and pds0101 primary completion](https://sec-api.dev/pdufa/pembrolizumab-keytruda-and-pds0101) | PDSB |  | completed | "NCT04260126 (Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-14 (ACTUAL); Lead Sponsor PDS Biotechnology Corp.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04260126)) |
| May 14, 2025 | [Emrelis (telisotuzumab vedotin-tllv) FDA approval](https://sec-api.dev/pdufa/telisotuzumab-vedotin-tllv) | ABBV |  | completed, approved | "Emrelis \| telisotuzumab vedotin-tllv \| 5/14/2025 \| To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 15, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/ex99-1.htm)) |
| May 15, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm)) |
| May 15, 2025 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/hura-ex99_1.htm)) |
| May 15, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/d66861dex991.htm)) |
| May 15, 2025 | [Sunshine Biopharma Inc. earnings report](https://sec-api.dev/companies/sbfm/catalysts) | SBFM |  | completed | ""We are thrilled to report strong financial results for the first quarter of 2025, with an 18% increase in revenues compared to the same period last year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/sunshine_ex9901.htm)) |
| May 15, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm)) |
| May 15, 2025 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000095017025072612/sepn-ex99_1.htm)) |
| May 15, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/ex99-1.htm)) |
| May 15, 2025 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Traws Pharma Reports First Quarter 2025 Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925048915/tm2515069d1_ex99-1.htm)) |
| May 15, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "-- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm)) |
| May 15, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_ex99-1.htm)) |
| May 15, 2025 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/exh_991.htm)) |
| May 15, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/ex99-1.htm)) |
| May 15, 2025 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/vtvt-20250331xexx991pressr.htm)) |
| May 15, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/ex99-1.htm)) |
| May 15, 2025 | [Rein Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rntx/catalysts) | RNTX |  | completed | "Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/d889805dex991.htm)) |
| May 15, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-ex99_1.htm)) |
| May 15, 2025 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495425005749/zom_ex991.htm)) |
| May 15, 2025 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000164117225010587/ex99-1.htm)) |
| May 15, 2025 | [FILSPARI (sparsentan) NDA/BLA acceptance](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On May 15, 2025, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted its supplemental New Drug Application ("sNDA") for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm)) |
| May 15, 2025 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390025043730/ea024225301ex99-1_adial.htm)) |
| May 15, 2025 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "15, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter 2025 ended March 31, 2025, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug development enhancements, and other operational progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/ex99-1.htm)) |
| May 15, 2025 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/tm2514971d1_ex99-1.htm)) |
| May 15, 2025 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/ex991_pressreleaseq125earn.htm)) |
| May 15, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm)) |
| May 15, 2025 | [NRX Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | completed | "WILMINGTON, Del., May 15th, 2025 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774925018000/ex_821626.htm)) |
| May 15, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515xexx991.htm)) |
| May 15, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_ex99-1.htm)) |
| May 15, 2025 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/dtil-ex99_1.htm)) |
| May 15, 2025 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/cntbq12025earningsrelease.htm)) |
| May 15, 2025 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio today reported its financial results for the quarter ended March 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/phio_ex9901.htm)) |
| May 15, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/ef20048561_ex99-1.htm)) |
| May 15, 2025 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/pyxs-ex99_1.htm)) |
| May 15, 2025 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/tivc-ex99_1.htm)) |
| May 15, 2025 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL - May 15, 2025 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000095017025072825/hcwb-ex99_1.htm)) |
| May 15, 2025 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525120329/d89129dex991.htm)) |
| May 15, 2025 | [Akari Therapeutics Plc earnings report](https://sec-api.dev/companies/aktx/catalysts) | AKTX |  | completed | "Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/aktx-ex99_1.htm)) |
| May 15, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "APTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/apvo-ex99_1.htm)) |
| May 15, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Multiple Sclerosis | withdrawn | "NCT04140305 (Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04140305)) |
| May 15, 2025 | [TRUTAKNA (atacicept) primary completion](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy; Berger Disease | completed | "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04716231)) |
| May 15, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | completed | "NCT05242484 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05242484)) |
| May 15, 2025 | [Scemblix (asciminib) primary completion](https://sec-api.dev/pdufa/asciminib) | NVS | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | completed | "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456191)) |
| May 15, 2025 | [CTX-009 primary completion](https://sec-api.dev/pdufa/ctx-009) | CMPX | Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer | completed | "NCT05513742 (A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Compass Therapeutics; Results First Posted 2026-07-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513742)) |
| May 15, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH | completed | "NCT06578949 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-06-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06578949)) |
| May 15, 2025 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250515, review_priority PRIORITY; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| May 16, 2025 | [Nuvaxovid (nuvaxovid) FDA approval](https://sec-api.dev/pdufa/nuvaxovid) | NVAX |  | completed, approved | "announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Biologics License Application ("BLA") for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/tm2515521d1_8k.htm)) |
| May 16, 2025 | [OS Therapies Inc earnings report](https://sec-api.dev/companies/ostx/catalysts) | OSTX |  | completed | "May 16, 2025 - OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1795091/000121390025044875/ea024245201ex99-1_ostherap.htm)) |
| May 16, 2025 | [Sovleplenib primary completion](https://sec-api.dev/pdufa/sovleplenib) | HCM | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05029635 (Phase III Study on HMPL-523 for Treatment of ITP): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-16 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05029635)) |
| May 19, 2025 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS | moderate hypertriglyceridemia with | completed, positive | "CARLSBAD, Calif., May 19, 2025 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk for atherosclerotic cardiovascular disease (ASCVD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/ef20049265_ex99-1.htm)) |
| May 19, 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP | antibiotic-resistant and difficult-to-treat bacterial infections, today | completed, positive | "On May 19, 2025, we announced positive topline data from the Phase 1b/2a diSArm study of intravenously administered AP-SA02 in complicated S. aureus bacteremia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921114/000110465926126277/armp-20260930x10q.htm)) |
| May 19, 2025 | [PM359 trial start](https://sec-api.dev/pdufa/pm359) | PRME |  | completed | "On May 19, 2025, the Company announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in CGD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812d8k.htm)) |
| May 19, 2025 | [PM359 interim data readout](https://sec-api.dev/pdufa/pm359) | PRME |  | completed, positive | "On May 19, 2025, the Company announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in CGD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812d8k.htm)) |
| May 19, 2025 | [Gsk3511294 (depemokimab) primary completion](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680)) |
| May 20, 2025 | [CERO THERAPEUTICS HOLDINGS, INC. trial start](https://sec-api.dev/companies/cero/catalysts) | CERO |  | completed | "First patient dosed on May 20, 2025 ⎼ No dose - limiting toxicity at 28 days ⎼ Encouraging PK response" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1870404/000121390025090107/ea025816601ex99-1_cero.htm)) |
| May 20, 2025 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250520, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| May 20, 2025 | [ProPhase Labs, Inc. earnings report](https://sec-api.dev/companies/prph/catalysts) | PRPH |  | completed | "Labs Announces Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/868278/000164117225011607/ex99-1.htm)) |
| May 20, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed | "On the afternoon of May 20, 2025, the Committee will discuss sBLA 761145/S-029, for DARZALEX FASPRO (daratumumab and hyaluronidase) injection, for subcutaneous use, submitted by Janssen Biotech, Inc. The proposed indication (use) is as monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma (SMM)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| May 20, 2025 | [Renal autologous cell therapy (react) primary completion](https://sec-api.dev/pdufa/renal-autologous-cell-therapy-react) | PROK | Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus | completed | "NCT05018416 (Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Prokidney." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05018416)) |
| May 20, 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide primary completion](https://sec-api.dev/pdufa/ihl-42x) | IXHL | Obstructive Sleep Apnea | completed | "NCT06146101 (RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Incannex Healthcare Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06146101)) |
| May 20, 2025 | [BMF-219 primary completion](https://sec-api.dev/pdufa/bmf-219) | BMEA | Type 1 Diabetes Mellitus | completed | "NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Biomea Fusion Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152042)) |
| May 21, 2025 | [Levosimendan trial start](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed | "- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the first patient has been dosed in the Phase 2, investigator-initiated OASIS trial to evaluate TNX-102 SL in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/ex99-01.htm)) |
| May 21, 2025 | [ZUSDURI (mitomycin) FDA advisory committee meeting](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "On the morning of May 21, 2025, the Committee will discuss new drug application (NDA) 215793, for (mitomycin) intravesical solution, submitted by UroGen Pharma, Inc. The proposed indication (use) is for the treatment of adult patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| May 21, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722)) |
| May 21, 2025 | [PHE885 primary completion](https://sec-api.dev/pdufa/phe885) | NVS | Multiple Myeloma | withdrawn | "NCT05172596 (PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172596)) |
| May 21, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06034743 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06034743)) |
| May 21, 2025 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817)) |
| May 21, 2025 | [Talzenna (talazoparib tosylate) FDA advisory committee meeting](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, negative | "On the afternoon of May 21, 2025, the Committee will discuss supplemental new drug application (sNDA) 211651/S-013, for TALZENNA (talazoparib) capsules, submitted by Pfizer Inc. The proposed indication (use) is in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| May 22, 2025 | [NOVAVAX INC FDA advisory committee meeting](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | scheduled | "Biological Products Advisory Committee meeting on May 22, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/tm2515521d1_8k.htm)) |
| May 22, 2025 | [Hydronidone topline data readout](https://sec-api.dev/pdufa/hydronidone) | GYRE |  | completed, met | "As previously disclosed on May 22, 2025, Gyre reported topline results from its Phase 3 trial in CHB-associated liver fibrosis demonstrating that Hydronidone met its primary endpoint, with 52.85% of treated patients achieving ≥1-stage fibrosis regression at Week 52, compared with 29.84% in the placebo group (p=0.0002), based on centralized, blinded Ishak histologic assessment." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000114036126000253/ny20062326x1_ex99-1.htm)) |
| May 22, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "•The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, and has been assigned a PDUFA action date of May 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm)) |
| May 22, 2025 | [Neopeptides trial start](https://sec-api.dev/pdufa/neopeptides) | EVAX |  | completed | "COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828253/000117184325003392/exh_991.htm)) |
| May 22, 2025 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "MA, May 22, 2025 - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/tm2515645d2_ex99-1.htm)) |
| May 22, 2025 | [Prolia® (denosumab) label expansion decision](https://sec-api.dev/pdufa/denosumab) | AMGN |  | completed, approved | "BLA125320 SUPPL-219 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22)) |
| May 22, 2025 | [Kalydeco (ivacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor) | VRTX |  | completed, approved | "NDA203188 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority PRIORITY; sponsor_name VERTEX PHARMS; product KALYDECO (IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203188%22)) |
| May 22, 2025 | [Lupron Depot (leuprolide acetate) label expansion decision](https://sec-api.dev/pdufa/leuprolide) | ABBV |  | completed, approved | "NDA020263 SUPPL-56 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ABBVIE ENDOCRINE INC; product LUPRON DEPOT-PED KIT (LEUPROLIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020263%22)) |
| May 22, 2025 | [Nucala (mepolizumab) label expansion decision](https://sec-api.dev/pdufa/mepolizumab) | GSK |  | completed, approved | "BLA125526 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22)) |
| May 22, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880)) |
| May 22, 2025 | [Bezuclastinib tablets (formulation a) primary completion](https://sec-api.dev/pdufa/bezuclastinib-tablets-formulation-a) | COGT | SSM; Mastocytosis, Indolent; Mastocytosis, Systemic | completed | "NCT05186753 ((Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186753)) |
| May 22, 2025 | [Part a: zibotentan (dose b) + dapagliflozin primary completion](https://sec-api.dev/pdufa/part-a-zibotentan-dose-b-dapagliflozin) | AZN | Liver Cirrhosis | withdrawn | "NCT05516498 (Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05516498)) |
| May 22, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-182 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 22, 2025 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA217242 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22)) |
| May 23, 2025 | [YUTREPIA (treprostinil) FDA approval](https://sec-api.dev/pdufa/treprostinil) | LQDA | PAH and PH-ILD in May 2025 | completed, approved | "As previously disclosed, the FDA granted approval of YUTREPIA™ for the treatment of PAH and PH-ILD on May 23, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_8k.htm)) |
| May 23, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-136 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 23, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | completed | "NCT05242471 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05242471)) |
| May 23, 2025 | [Dusquetide primary completion](https://sec-api.dev/pdufa/dusquetide) | SNGX | Behçet Disease | completed | "NCT06386744 (Dusquetide for the Treatment of Behcet's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Soligenix; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06386744)) |
| May 23, 2025 | [Canvuparatide primary completion](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | completed | "NCT06465108 (Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465108)) |
| May 23, 2025 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-133 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 24, 2025 | [YUTREPIA (treprostinil) PDUFA date](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | completed, approved | "Does not impact FDA's ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925046935/tm2514743d1_ex99-1.htm)) |
| May 24, 2025 | [DPI (dpi) PDUFA date](https://sec-api.dev/pdufa/dpi) | LQDA |  | scheduled | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, the day after regulatory exclusivity expires for Tyvaso DPI®." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm)) |
| May 26, 2025 | [MK-6482 PDUFA date](https://sec-api.dev/pdufa/mk-6482) | MRK |  | scheduled | "The FDA set a PDUFA date of May 26, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| May 26, 2025 | [Eftilagimod alfa trial start](https://sec-api.dev/pdufa/eftilagimod-alfa) | IMMP |  | completed | "the Company), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312525127970/d51427dex991.htm)) |
| May 26, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis | completed | "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04717414)) |
| May 27, 2025 | [Vaxart, Inc. trial start](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "SOUTH SAN FRANCISCO, Calif., May 27, 2025 — Vaxart, Inc. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/ex_824166.htm)) |
| May 27, 2025 | [Tivoxavir marboxil NDA/BLA submission](https://sec-api.dev/pdufa/tivoxavir-marboxil) | TRAW |  | completed | "Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/tm2516160d1_ex99-2.htm)) |
| May 27, 2025 | [GSK3036656 primary completion](https://sec-api.dev/pdufa/gsk3036656) | GSK | Tuberculosis | completed | "NCT05382312 (Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382312)) |
| May 27, 2025 | [ALXN1720 primary completion](https://sec-api.dev/pdufa/alxn1720) | AZN | Generalized Myasthenia Gravis | completed | "NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05556096)) |
| May 27, 2025 | [Icosema primary completion](https://sec-api.dev/pdufa/icosema) | NVO | Type 2 Diabetes | completed | "NCT06269107 (A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269107)) |
| May 27, 2025 | [VX-993 primary completion](https://sec-api.dev/pdufa/vx-993) | VRTX | Acute Pain | completed | "NCT06619847 (A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619847)) |
| May 28, 2025 | [Enobosarm topline data readout](https://sec-api.dev/pdufa/enobosarm) | VERU |  | completed, positive | "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925026072/veru20250630_10q.htm)) |
| May 28, 2025 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | VERU |  | completed, positive | "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study portion during the 16 weeks of active weight loss that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm)) |
| May 28, 2025 | [ET-400 PDUFA date](https://sec-api.dev/pdufa/et-400) | ETON |  | scheduled | "The new PDUFA goal date is May 28, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/eton20250205_8k.htm)) |
| May 28, 2025 | [Tryptyr (acoltremon) FDA approval](https://sec-api.dev/pdufa/acoltremon) | ALC | To treat the signs and symptoms of dry eye disease | completed, approved | "Tryptyr \| acoltremon \| 5/28/2025 \| To treat the signs and symptoms of dry eye diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 28, 2025 | [KHINDIVI® (hydrocortisone) FDA approval](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | completed, approved | "DEER PARK, Ill., MAY 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925018698/ex_822865.htm)) |
| May 28, 2025 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-small Cell Lung Cancer | withdrawn | "NCT04933695 (A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04933695)) |
| May 28, 2025 | [OG-6219 primary completion](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646)) |
| May 28, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05624268 (Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624268)) |
| May 28, 2025 | [Lcz primary completion](https://sec-api.dev/pdufa/lcz) | NVS | Hypertension | completed | "NCT06236061 (Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236061)) |
| May 29, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/exhibit9912025529.htm)) |
| May 29, 2025 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/ef20049462_ex99-1.htm)) |
| May 29, 2025 | [ARTEMIS (artemis) trial start](https://sec-api.dev/pdufa/artemis) | ESLA | cancer and autoimmune diseases, today | completed | "Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/ea024370301ex99-1_estrella.htm)) |
| May 30, 2025 | [BioLineRx Ltd. trial start](https://sec-api.dev/companies/blrx/catalysts) | BLRX |  | completed | "BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891325002019/exhibit_1.htm)) |
| May 30, 2025 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Ulcerative Colitis; Crohn's Disease | completed | "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04738942)) |
| May 30, 2025 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Non-small Cell Lung Cancer; NSCLC | withdrawn | "NCT04746924 (A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-05-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04746924)) |
| May 30, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Plaque Psoriasis; Scalp Psoriasis | completed | "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05272150)) |
| May 30, 2025 | [Nx-13 250mg primary completion](https://sec-api.dev/pdufa/nx-13) | ABBV | Ulcerative Colitis | withdrawn | "NCT05785715 (Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785715)) |
| May 30, 2025 | [Zavzpret ® (zavegepant) primary completion](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048)) |
| May 30, 2025 | [Alcestobart primary completion](https://sec-api.dev/pdufa/alcestobart) | ONC |  | completed | "NCT06010303 (A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010303)) |
| May 30, 2025 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | completed | "NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230523)) |
| May 30, 2025 | [Biorphen (phenylephrine hydrochloride) FDA approval](https://sec-api.dev/pdufa/phenylephrine) | RDY |  | completed, approved | "NDA216830 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250530, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (PHENYLEPHRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216830%22)) |
| May 31, 2025 | [Moderna, Inc. PDUFA date](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | scheduled | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| May 2025 | [Liq861 inhaled treprostinil primary completion](https://sec-api.dev/pdufa/liq861-inhaled-treprostinil) | LQDA | Primary Pulmonary Hypertension | delayed | "NCT03992755 (Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-31 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03992755)) |

Other months: https://sec-api.dev/fda-calendar/2025-04 , https://sec-api.dev/fda-calendar/2025-06. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates May 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-05

```bibtex
@misc{secapidev_fda_calendar_2025_05_20261116,
  title        = {PDUFA dates May 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-05}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_05_20261116","title":"PDUFA dates May 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-05","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
